{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:54:56Z","timestamp":1772783696757,"version":"3.50.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","funder":[{"name":"Directorate General of Higher Education (DIKTI) Scholarship"},{"DOI":"10.13039\/501100006667","name":"Ministry of National Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. J. Clin. Oncol."],"DOI":"10.1093\/jjco\/hyw192","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T12:05:37Z","timestamp":1480939537000},"source":"Crossref","is-referenced-by-count":11,"title":["Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis"],"prefix":"10.1093","author":[{"given":"Didik","family":"Setiawan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Luttjeboer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koen B.","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan C.","family":"Wilschut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,1,1]]},"reference":[{"key":"2017010717102319000_hyw192v2.1","first-page":"349","article-title":"Cervical cancer in the Asian pacific-epidemiology, screening and treatment","volume":"5","author":"Moore","year":"2003","journal-title":"Asian Pac J Cancer Prev"},{"key":"2017010717102319000_hyw192v2.2","unstructured":"Ferlay J , Soerjomataram I , Ervik M , et al . GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer [Internet]. 2013 Available: http:\/\/globocan.iarc.fr (17 August 2014, date last accessed)."},{"key":"2017010717102319000_hyw192v2.3","doi-asserted-by":"crossref","unstructured":"Shah KV . Asia Pacific: cervical cancer screening and human papillomavirus vaccination policy and delivery. Vaccine 2008;26. doi:10.1016\/j.vaccine.2008.06.033.","DOI":"10.1016\/j.vaccine.2008.06.033"},{"key":"2017010717102319000_hyw192v2.4","first-page":"1074","article-title":"Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis","volume":"39","author":"Orth","year":"1979","journal-title":"Cancer Res"},{"key":"2017010717102319000_hyw192v2.5","first-page":"4677","article-title":"Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers","volume":"49","author":"zur Hausen","year":"1989","journal-title":"Cancer Res"},{"key":"2017010717102319000_hyw192v2.6","doi-asserted-by":"publisher","DOI":"10.1086\/657321"},{"key":"2017010717102319000_hyw192v2.7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.1.1-17.2003"},{"key":"2017010717102319000_hyw192v2.8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv086"},{"key":"2017010717102319000_hyw192v2.9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2051013614557476","article-title":"Human papilloma virus vaccination: impact and recommendations across the world","volume":"3","author":"Bonanni","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"2017010717102319000_hyw192v2.10","unstructured":"Indications CERVARIX\u00ae is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18 [see Clinical Studies (14)]: \u2022 cervical cancer, \u2022 cervical intraepithelial neoplasia (CIN) grade 2 or w. 2009; 1\u201327."},{"key":"2017010717102319000_hyw192v2.11","unstructured":"Girls and Women GARDASIL\u00ae is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine\u202f: Genital warts (condyloma acuminata) caused. 2006;"},{"key":"2017010717102319000_hyw192v2.12","unstructured":"index @ www.gardasil.com [Internet]. Available: http:\/\/www.gardasil.com\/"},{"key":"2017010717102319000_hyw192v2.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61248-4"},{"key":"2017010717102319000_hyw192v2.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061741"},{"key":"2017010717102319000_hyw192v2.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70187-1"},{"key":"2017010717102319000_hyw192v2.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3493"},{"key":"2017010717102319000_hyw192v2.17","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29532"},{"key":"2017010717102319000_hyw192v2.18","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/INF.0000000000000460","article-title":"Long-term immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls","volume":"33","author":"Schwarz","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2017010717102319000_hyw192v2.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-004-0501-4"},{"key":"2017010717102319000_hyw192v2.20","doi-asserted-by":"publisher","DOI":"10.1086\/521679"},{"key":"2017010717102319000_hyw192v2.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.043"},{"key":"2017010717102319000_hyw192v2.22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/13625187.2013.801953","article-title":"Impact of HPV16\/18 vaccination on quality of life: a pilot study","volume":"18","author":"Eriksson","year":"2013","journal-title":"Eur J Contracept Reprod Heal care"},{"key":"2017010717102319000_hyw192v2.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.04.025"},{"key":"2017010717102319000_hyw192v2.24","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.7.11278"},{"key":"2017010717102319000_hyw192v2.25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Reprinted from Annals of Internal Medicine)","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"2017010717102319000_hyw192v2.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2017010717102319000_hyw192v2.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2017010717102319000_hyw192v2.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2017010717102319000_hyw192v2.29","unstructured":"Higgins JP , Green S . Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 2011. Available: http:\/\/handbook.cochrane.org\/chapter_9\/9_5_2_identifying_and_measuring_heterogeneity.htm"},{"key":"2017010717102319000_hyw192v2.30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1525-1438.2007.01123.x","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects","volume":"18","author":"Kang","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"2017010717102319000_hyw192v2.31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/IGC.0b013e3181a23c0e","article-title":"Immunogenicity, reactogenicity, and safety of human papillomavirus 16\/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7","volume":"19","author":"Konno","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"2017010717102319000_hyw192v2.32","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3346\/jkms.2010.25.8.1197","article-title":"Vaccination with a human papillomavirus (HPV)-16\/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10\u201314 years","volume":"25","author":"Kim","year":"2010","journal-title":"J Korean Med Sci"},{"key":"2017010717102319000_hyw192v2.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2009.01167.x"},{"key":"2017010717102319000_hyw192v2.34","first-page":"171","article-title":"Human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and safety in healthy Chinese women from Hong Kong","volume":"16","author":"Ngan","year":"2010","journal-title":"Hong Kong Med J"},{"key":"2017010717102319000_hyw192v2.35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3802\/jgo.2011.22.2.67","article-title":"Human papillomavirus 16\/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and safety in 15-25 years old healthy Korean women","volume":"22","author":"Kim","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"2017010717102319000_hyw192v2.36","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyr173"},{"key":"2017010717102319000_hyw192v2.37","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1016\/j.vaccine.2012.02.079","article-title":"Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females","volume":"30","author":"Li","year":"2012","journal-title":"Vaccine"},{"key":"2017010717102319000_hyw192v2.38","first-page":"2","article-title":"Immunogenicity and safety of the AS04-adjuvanted human papillomavirus-16\/18 cervical cancer vaccine in malaysian women aged 18-35 years: a randomized controlled trial","volume":"69","author":"Lim","year":"2014","journal-title":"Med J Malaysia"},{"key":"2017010717102319000_hyw192v2.39","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.28897","article-title":"Efficacy, immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomised controlled trial","volume":"2622","author":"Zhu","year":"2014","journal-title":"Int J Cancer"},{"key":"2017010717102319000_hyw192v2.40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23260"},{"key":"2017010717102319000_hyw192v2.41","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0461"},{"key":"2017010717102319000_hyw192v2.42","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2017010717102319000_hyw192v2.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60691-7"},{"key":"2017010717102319000_hyw192v2.44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis619"},{"key":"2017010717102319000_hyw192v2.45","doi-asserted-by":"crossref","unstructured":"Kreimer R , Schiffman M , Herrero R , et al . Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int J Cancer 2012;doi:10.1002\/ijc.26349.","DOI":"10.1002\/ijc.26349"},{"key":"2017010717102319000_hyw192v2.46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-13"},{"key":"2017010717102319000_hyw192v2.47","unstructured":"Davies W India Has Most Cervical Cancer Deaths [Internet]. 2013 Available: http:\/\/blogs.wsj.com\/indiarealtime\/2013\/05\/10\/india-has-highest-number-of-cervical-cancer-deaths\/ (30 December 2014, date last accessed)"},{"key":"2017010717102319000_hyw192v2.48","first-page":"405","article-title":"Epidemiology of cervical cancer with special focus on India","volume":"7","author":"Sreedevi","year":"2015","journal-title":"Int J Womens Health"},{"key":"2017010717102319000_hyw192v2.49","unstructured":"Siddaway A . What is a systematic literature review and how do I do one? Univ Stirling. 2014; 1\u201313. Available: https:\/\/www.stir.ac.uk\/media\/schools\/management\/documents\/centregradresearch\/How to do a systematic literature review and meta-analysis.pdf"},{"key":"2017010717102319000_hyw192v2.50","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1097\/00000539-200412000-00057","article-title":"Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting","volume":"99","author":"Lee","year":"2004","journal-title":"Anesth Analg"},{"key":"2017010717102319000_hyw192v2.51","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/sim.6844","article-title":"Low-event-rate meta-analyses of clinical trials: Implementing good practices","volume":"35","author":"Shuster","year":"2016","journal-title":"Stat Med"},{"key":"2017010717102319000_hyw192v2.52","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/14760584.2014.990386","article-title":"The cost\u2013effectiveness of HPV vaccination in addition to screening: a Dutch perspective","volume":"14","author":"Setiawan","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"2017010717102319000_hyw192v2.53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089974"},{"key":"2017010717102319000_hyw192v2.54","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4144"},{"key":"2017010717102319000_hyw192v2.55","first-page":"483","article-title":"Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis","volume":"110","author":"Rey-Ares","year":"2012","journal-title":"Arch Argent Pediatr"},{"key":"2017010717102319000_hyw192v2.56","doi-asserted-by":"crossref","unstructured":"Suwantika AA , Postma MJ . Expanding access to non-traditional vaccines\u202f: a perspective from Indonesia Expanding access to non-traditional vaccines\u202f: a perspective from Indonesia. 2016;584 doi:10.1586\/14760584.2014.944165.","DOI":"10.1586\/14760584.2014.944165"},{"key":"2017010717102319000_hyw192v2.57","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70237-2"},{"key":"2017010717102319000_hyw192v2.58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054583"},{"key":"2017010717102319000_hyw192v2.59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-9276-10-27","article-title":"Global challenges of implementing human papillomavirus vaccines","volume":"10","author":"Graham","year":"2011","journal-title":"Int J Equity Health"},{"key":"2017010717102319000_hyw192v2.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.016"},{"key":"2017010717102319000_hyw192v2.61","doi-asserted-by":"crossref","unstructured":"Guerra FA . Delays in immunization have potentially serious health consequences. 2007;9:143\u2013148.","DOI":"10.2165\/00148581-200709030-00002"},{"key":"2017010717102319000_hyw192v2.62","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-498"},{"key":"2017010717102319000_hyw192v2.63","doi-asserted-by":"publisher","DOI":"10.1111\/jog.12052"},{"key":"2017010717102319000_hyw192v2.64","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/11597750-000000000-00000","article-title":"The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis","volume":"30","author":"Connolly","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"2017010717102319000_hyw192v2.65","doi-asserted-by":"crossref","unstructured":"Sachs JD . Macroeconomics and Health: Investing in Health for Economic Development [Internet]. Geneva; 2001 Jun. doi:10.1038\/nm0602-551b","DOI":"10.1038\/nm0602-551b"},{"key":"2017010717102319000_hyw192v2.66","unstructured":"Nelson R . EU Recommends Approval of Gardasil 9 Vaccine [Internet]. 2015 Available: http:\/\/www.medscape.com\/viewarticle\/562858_print (20 April 2015, date last accessed)"},{"key":"2017010717102319000_hyw192v2.67","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00414-3"},{"key":"2017010717102319000_hyw192v2.68","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00047-9"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T19:01:52Z","timestamp":1601233312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hyw192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":68,"alternative-id":["10.1093\/jjco\/hyw192"],"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyw192","relation":{},"ISSN":["0368-2811","1465-3621"],"issn-type":[{"value":"0368-2811","type":"print"},{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,1]]}}}